

Jason Roszik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4579391/publications.pdf>

Version: 2024-02-01

173
papers

14,418
citations

57752

44
h-index

22161

113
g-index

177
all docs

177
docs citations

177
times ranked

25125
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e16-e24.	1.9	1
2	Investigating the natural history and prognostic nature of NTRK gene fusions in solid tumors. <i>Investigational New Drugs</i> , 2022, 40, 157-162.	2.6	2
3	Single-Cell Sequencing: Current Applications in Precision Onco-Genomics and Cancer Therapeutics. <i>Cancers</i> , 2022, 14, 657.	3.7	10
4	Interplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor growth and influences patient survival in melanoma. <i>Cell Death and Disease</i> , 2022, 13, 117.	6.3	21
5	Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma. <i>Gastroenterology</i> , 2022, 162, 1303-1318.e18.	1.3	26
6	Loss of ubiquitin-specific peptidase 18 destabilizes 14-3-3 σ protein and represses lung cancer metastasis. <i>Cancer Biology and Therapy</i> , 2022, 23, 265-280.	3.4	6
7	Cytospin-A Regulates Colorectal Cancer Cell Division and Migration by Modulating Stability of Microtubules and Actin Filaments. <i>Cancers</i> , 2022, 14, 1977.	3.7	3
8	Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102. <i>Clinical Cancer Research</i> , 2022, 28, 3573-3589.	7.0	12
9	Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600E Mutant Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 871-878.	4.1	23
10	Real-world Studies Link NSAID Use to Improved Overall Lung Cancer Survival. <i>Cancer Research Communications</i> , 2022, 2, 590-601.	1.7	0
11	Characterizing the genomic landscape of PIK3CA alterations from 121,221 adult patients with cancer: The next tissue-agnostic target?. <i>Journal of Clinical Oncology</i> , 2022, 40, 3088-3088.	1.6	0
12	Association between telehealth and adherence with patient-reported outcomes (PRO)-based remote symptom monitoring among adolescent/young adults (AYA), middle age, and older adults with cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1513-1513.	1.6	2
13	17 β -Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury. <i>Hepatology</i> , 2021, 73, 1701-1716.	7.3	38
14	A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 477-489.	4.1	9
15	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. <i>Molecular Cancer Research</i> , 2021, 19, 395-402.	3.4	7
16	Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1101-1113.	4.2	18
17	iNOS Associates With Poor Survival in Melanoma: A Role for Nitric Oxide in the PI3K-AKT Pathway Stimulation and PTEN S-Nitrosylation. <i>Frontiers in Oncology</i> , 2021, 11, 631766.	2.8	10
18	Targeting KRAS in Cancer: Promising Therapeutic Strategies. <i>Cancers</i> , 2021, 13, 1204.	3.7	40

#	ARTICLE	IF	CITATIONS
19	IL-1 β Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma. <i>Journal of Immunology</i> , 2021, 206, 1966-1975.	0.8	12
20	Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches. <i>Cancer Discovery</i> , 2021, 11, 1024-1039.	9.4	56
21	Dosing, drug reduction, drug interruption, and drug discontinuation rates among U.S. FDA approved tyrosine kinase inhibitors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3112-3112.	1.6	2
22	Prognostic factors in RET dependent cancers treated with RET inhibitors in early phase clinical trials.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3117-3117.	1.6	0
23	Association of Edmonton Symptom Assessment System Global Distress Score With Overall Survival in Patients With Advanced Cancer. <i>JAMA Network Open</i> , 2021, 4, e2117295.	5.9	14
24	Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. , 2021, 9, e002531.		24
25	Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. <i>Gastroenterology</i> , 2021, 161, 196-210.	1.3	23
26	Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma. , 2021, 9, e003220.		20
27	Hallmarks of RET and Co-occurring Genomic Alterations in <i>RET</i> -aberrant Cancers. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1769-1776.	4.1	23
28	Genome-wide mapping of binding sites of the transposase-derived SETMAR protein in the human genome. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 4032-4041.	4.1	3
29	ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1663-1670.	7.0	30
30	The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell-Mediated Immunotherapies. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 500-511.	4.1	58
31	18F-sodium fluoride positron emission tomography (NaF-18-PET/CT) radiomic signatures to evaluate responses to alpha-particle Radium-223 dichloride therapy in osteosarcoma metastases. <i>Current Problems in Cancer</i> , 2021, 45, 100797.	2.0	3
32	Landscape of Immune-Related Markers and Potential Therapeutic Targets in Soft Tissue Sarcoma. <i>Cancers</i> , 2021, 13, 5249.	3.7	4
33	Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications. <i>Current Problems in Cancer</i> , 2021, 45, 100794.	2.0	4
34	The Ubiquitin-Specific Peptidase USP18 Promotes Lipolysis, Fatty Acid Oxidation, and Lung Cancer Growth. <i>Molecular Cancer Research</i> , 2021, 19, 667-677.	3.4	18
35	The EMT activator ZEB1 accelerates endosomal trafficking to establish a polarity axis in lung adenocarcinoma cells. <i>Nature Communications</i> , 2021, 12, 6354.	12.8	20
36	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. <i>Science</i> , 2021, 374, 1632-1640.	12.6	369

#	ARTICLE	IF	CITATIONS
37	Checkpoint Genes at the Cancer Side of the Immunological Synapse in Bladder Cancer. <i>Translational Oncology</i> , 2020, 13, 193-200.	3.7	16
38	Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. <i>Nature Communications</i> , 2020, 11, 5332.	12.8	15
39	Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy. , 2020, 8, e000960.		31
40	Opportunities for Single-Cell Sequencing Technologies and Data Science. <i>Cancers</i> , 2020, 12, 3433.	3.7	1
41	Current Targeted Therapies for the Fight against Non-Small Cell Lung Cancer. <i>Pharmaceuticals</i> , 2020, 13, 374.	3.8	11
42	Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. <i>ESMO Open</i> , 2020, 5, e001073.	4.5	1
43	Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. <i>ESMO Open</i> , 2020, 5, e000799.	4.5	45
44	Dual inhibition of BRAF and mTOR in BRAFV600E-mutant pediatric, adolescent, and young adult brain tumors. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005041.	1.2	6
45	Phase I Study of P-cadherinâ€‘targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 5830-5842.	7.0	17
46	The Expression of CD74-Regulated Inflammatory Markers in Stage IV Melanoma: Risk of CNS Metastasis and Patient Survival. <i>Cancers</i> , 2020, 12, 3754.	3.7	3
47	779P Validation of prognostic scores in patients with metastatic bladder carcinoma (mBC) enrolled in early phase clinical trials. <i>Annals of Oncology</i> , 2020, 31, S597-S598.	1.2	0
48	Cancer Genetics and Therapeutic Opportunities in Urologic Practice. <i>Cancers</i> , 2020, 12, 710.	3.7	3
49	Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1165-1172.	4.1	15
50	Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> -V600-Mutant Non-Melanoma Cancers. <i>Cancer Discovery</i> , 2020, 10, 657-663.	9.4	93
51	Immuno-genomic landscape of osteosarcoma. <i>Nature Communications</i> , 2020, 11, 1008.	12.8	143
52	Targeting the SAGA and ATAC Transcriptional Coactivator Complexes in MYC-Driven Cancers. <i>Cancer Research</i> , 2020, 80, 1905-1911.	0.9	17
53	Systemic Therapy for Mucosal, Acral, and Uveal Melanoma. , 2020, , 1301-1335.		2
54	The prevalence of KRASG12C mutations utilizing circulating tumor DNA (ctDNA) in 80,911 patients with cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3547-3547.	1.6	6

#	ARTICLE	IF	CITATIONS
55	Therapeutic vulnerabilities among KRAS G12C mutant (mut) advanced cancers based on co-alteration (co-alt) patterns.. Journal of Clinical Oncology, 2020, 38, 3625-3625.	1.6	8
56	Phase I clinical trials as a therapeutic option for patients with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2020, 38, 5073-5073.	1.6	0
57	Integrating PROs with prognostic value into oncologic care: High ESAS global distress score associated with lower overall survival in advanced cancer patients.. Journal of Clinical Oncology, 2020, 38, 12021-12021.	1.6	0
58	Drugging the R-loop interactome: RNA-DNA hybrid binding proteins as targets for cancer therapy. DNA Repair, 2019, 84, 102642.	2.8	28
59	Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy. Molecular Cancer Therapeutics, 2019, 18, 1775-1786.	4.1	21
60	The role of EGFR inhibitor (EGFRi) in immune cell infiltration and CD8+ T-cell activation in EGFR mutant lung cancer. Annals of Oncology, 2019, 30, v2.	1.2	2
61	Clinical study of personalized neoantigen peptide vaccination in advanced NSCLC patients. Annals of Oncology, 2019, 30, v478-v479.	1.2	2
62	Elevated Endogenous SDHA Drives Pathological Metabolism in Highly Metastatic Uveal Melanoma. , 2019, 60, 4187.		30
63	Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets. Cancers, 2019, 11, 1283.	3.7	19
64	TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanoma. Cancer Immunology, Immunotherapy, 2019, 68, 1493-1500.	4.2	18
65	Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature. Cancer Immunology, Immunotherapy, 2019, 68, 1515-1526.	4.2	14
66	A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma. Clinical Cancer Research, 2019, 25, 6429-6442.	7.0	61
67	Immune response changes in HPV-related vulvar malignancy. Gynecologic Oncology, 2019, 154, 65-66.	1.4	0
68	Pilot Study of Circulating Tumor Cells in Early-Stage and Metastatic Uveal Melanoma. Cancers, 2019, 11, 856.	3.7	31
69	MAGE-A3 Is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers, 2019, 11, 677.	3.7	20
70	Precision Oncology in Sarcomas: Divide and Conquer. JCO Precision Oncology, 2019, 3, 1-16.	3.0	14
71	Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma. Case Reports in Oncology, 2019, 12, 7-13.	0.7	14
72	Arginine Metabolism Regulates Nitric Oxide Production in Melanoma Tumor Microenvironment to Provide Survival Advantage to Tumor Cells. , 2019, , 113-122.		0

#	ARTICLE	IF	CITATIONS
73	Mechanisms of nuclear content loading to exosomes. <i>Science Advances</i> , 2019, 5, eaax8849.	10.3	176
74	Lymphocyte-specific protein tyrosine kinase expression predicts survival in ovarian high-grade serous carcinoma. <i>Gynecologic Oncology</i> , 2019, 154, 64-65.	1.4	3
75	Beyond Autoantibodies: Biologic Roles of Human Autoreactive B Cells in Rheumatoid Arthritis Revealed by RNA Sequencing. <i>Arthritis and Rheumatology</i> , 2019, 71, 529-541.	5.6	17
76	Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 421-436.	4.1	10
77	The lncRNA RMEL3 protects immortalized cells from serum withdrawal-induced growth arrest and promotes melanoma cell proliferation and tumor growth. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 303-314.	3.3	17
78	The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 1650-1663.	7.0	43
79	Systemic Therapy for Mucosal, Acral and Uveal Melanoma. , 2019, , 1-37.		1
80	Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3604-3604.	1.6	8
81	The landscape of <i>RET</i> alterations from 56,970 adult patients with cancer: Clinical implications.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3106-3106.	1.6	2
82	Repression of GCN5 expression or activity attenuates c-MYC expression in non-small cell lung cancer. <i>American Journal of Cancer Research</i> , 2019, 9, 1830-1845.	1.4	11
83	The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. <i>Clinical Cancer Research</i> , 2018, 24, 3366-3376.	7.0	73
84	Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1595-1601.	4.1	30
85	Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. <i>JAMA Oncology</i> , 2018, 4, 1085.	7.1	62
86	Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. <i>Cell Metabolism</i> , 2018, 27, 977-987.e4.	16.2	398
87	Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 1913-1918.	7.1	64
88	Evidence for the ISG15-Specific Deubiquitinase USP18 as an Antineoplastic Target. <i>Cancer Research</i> , 2018, 78, 587-592.	0.9	43
89	The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 777-786.	6.3	58
90	Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018, 105, 1621-1626.	1.3	5

#	ARTICLE	IF	CITATIONS
91	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. <i>Cancer Cell</i> , 2018, 33, 690-705.e9.	16.8	478
92	Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology. <i>Current Oncology Reports</i> , 2018, 20, 37.	4.0	27
93	Alterations of microRNAs throughout the malignant evolution of cutaneous squamous cell carcinoma: the role of miR-497 in epithelial to mesenchymal transition of keratinocytes. <i>Oncogene</i> , 2018, 37, 218-230.	5.9	43
94	Biological Validation of RNA Sequencing Data From Formalin-Fixed Paraffin-Embedded Primary Melanomas. <i>JCO Precision Oncology</i> , 2018, 2018, 1-19.	3.0	19
95	High-Throughput Architecture for Discovering Combination Cancer Therapeutics. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-12.	2.1	9
96	Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report. <i>Journal of Global Oncology</i> , 2018, 4, 1-6.	0.5	24
97	Analysis of <i>MDM2</i> Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14.	3.0	39
98	Commentary: Nuclear dynamics of the Set1C subunit Spp1 prepares meiotic recombination sites for break formation. <i>Frontiers in Genetics</i> , 2018, 9, 496.	2.3	0
99	Editorial: Targeting Metabolism in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 2029.	4.8	5
100	RNA editing derived epitopes function as cancer antigens to elicit immune responses. <i>Nature Communications</i> , 2018, 9, 3919.	12.8	120
101	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- β Superfamily. <i>Cell Systems</i> , 2018, 7, 422-437.e7.	6.2	134
102	Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 2102.	4.8	33
103	Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10810-E10811.	7.1	5
104	Mining Public Databases for Precision Oncology. <i>Trends in Cancer</i> , 2018, 4, 463-465.	7.4	13
105	Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. <i>Clinical Cancer Research</i> , 2018, 24, 4416-4428.	7.0	89
106	Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 1591.	4.8	134
107	mTOR at the Transmitting and Receiving Ends in Tumor Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 578.	4.8	35
108	Impact of L-Arginine Metabolism on Immune Response and Anticancer Immunotherapy. <i>Frontiers in Oncology</i> , 2018, 8, 67.	2.8	105

#	ARTICLE	IF	CITATIONS
109	Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. <i>Journal of Clinical Investigation</i> , 2018, 128, 1338-1354.	8.2	64
110	Targeting iNOS to increase efficacy of immunotherapies. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1105-1108.	3.3	49
111	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	689
112	Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer. <i>Molecular Cancer Research</i> , 2017, 15, 905-914.	3.4	28
113	Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. <i>Cancer Immunology Research</i> , 2017, 5, 319-329.	3.4	25
114	4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells. <i>Cancer Immunology Research</i> , 2017, 5, 439-445.	3.4	45
115	Clinicopathological features and clinical outcomes associated with TP53 and BRAF ^N mutations in cutaneous melanoma patients. <i>Cancer</i> , 2017, 123, 1372-1381.	4.1	36
116	Biophysical characterization of histone H3.3 K27M point mutation. <i>Biochemical and Biophysical Research Communications</i> , 2017, 490, 868-875.	2.1	12
117	SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity. <i>Cancer Immunology Research</i> , 2017, 5, 618-629.	3.4	34
118	The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1280-1287.	1.1	57
119	P2.01-054 Lung Cancer PD-L1 mRNA Expression Profile and Clinical Outcomes - An Analysis From The Cancer Genome Atlas and Cancer Cell Line Encyclopedia. <i>Journal of Thoracic Oncology</i> , 2017, 12, S818-S819.	1.1	0
120	Towards precision oncology in RET-aberrant cancers. <i>Cell Cycle</i> , 2017, 16, 813-814.	2.6	17
121	Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. <i>Clinical Cancer Research</i> , 2017, 23, 4027-4034.	7.0	34
122	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017, 2, .	3.8	120
123	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. <i>Cell Reports</i> , 2017, 18, 2780-2794.	6.4	416
124	The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope. <i>Current Oncology Reports</i> , 2017, 19, 78.	4.0	32
125	HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. <i>Nature Communications</i> , 2017, 8, 451.	12.8	107
126	In Silico Restriction Enzyme Digests to Minimize Mapping Bias in Genomic Sequencing. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017, 6, 66-67.	4.1	5

#	ARTICLE	IF	CITATIONS
127	Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter. <i>Clinical Cancer Research</i> , 2017, 23, 6151-6164.	7.0	58
128	Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. <i>Cancer Cell</i> , 2017, 32, 204-220.e15.	16.8	642
129	Recent advances in genomic profiling of adenosquamous carcinoma of the pancreas. <i>Journal of Pathology</i> , 2017, 243, 271-272.	4.5	17
130	mTORC2 Promotes Tumorigenesis via Lipid Synthesis. <i>Cancer Cell</i> , 2017, 32, 807-823.e12.	16.8	282
131	Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. <i>Scientific Reports</i> , 2017, 7, 15963.	3.3	21
132	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. <i>Cell</i> , 2017, 171, 950-965.e28.	28.9	738
133	The potential role of platelets in the consensus molecular subtypes of colorectal cancer. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 273-288.	5.9	37
134	Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	41
135	Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. <i>Clinical Sarcoma Research</i> , 2017, 7, 11.	2.3	61
136	Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. <i>Leukemia</i> , 2017, 31, 234-237.	7.2	30
137	Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators. <i>Frontiers in Immunology</i> , 2017, 8, 689.	4.8	55
138	A tool for discovering drug sensitivity and gene expression associations in cancer cells. <i>PLoS ONE</i> , 2017, 12, e0176763.	2.5	29
139	Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target. <i>Frontiers in Immunology</i> , 2017, 8, 1975.	4.8	18
140	Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11008-11008.	1.6	32
141	Correlation of circulating PD-L2 levels with outcomes of therapy with the anti-PD-1 antibody pembrolizumab (P) in patients (pts) with advanced soft tissue sarcomas (STS): Biomarker analysis of SARC028.. <i>Journal of Clinical Oncology</i> , 2017, 35, 60-60.	1.6	3
142	The ISG15-specific protease USP18 regulates stability of PTEN. <i>Oncotarget</i> , 2017, 8, 3-14.	1.8	52
143	Comparative analysis of the <i>GNAQ</i> , <i>GNA11</i> , <i>SF3B1</i> , and <i>EIF1AX</i> driver mutations in melanoma and across the cancer spectrum. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 470-473.	3.3	18
144	Microsomal <i>PGE2</i> synthase-1 regulates melanoma cell survival and associates with melanoma disease progression. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 297-308.	3.3	22

#	ARTICLE	IF	CITATIONS
145	Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Resistant Refractory Metastatic Melanoma. <i>JAMA Oncology</i> , 2016, 2, 1056.	7.1	41
146	NLR5/MHC class I transactivator is a target for immune evasion in cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 5999-6004.	7.1	198
147	IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation. <i>Cancer Immunology Research</i> , 2016, 4, 983-994.	3.4	34
148	Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2442-2454.	4.1	47
149	Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. <i>Cell</i> , 2016, 167, 397-404.e9.	28.9	1,009
150	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. <i>BMC Medicine</i> , 2016, 14, 168.	5.5	106
151	Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. <i>Scientific Reports</i> , 2016, 6, 35848.	3.3	127
152	Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. <i>Scientific Reports</i> , 2016, 6, 19649.	3.3	15
153	Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography. <i>Molecular Imaging and Biology</i> , 2016, 18, 838-848.	2.6	22
154	Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 202-216.	9.4	1,158
155	Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 3016-3024.	7.0	39
156	Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 374-382.	7.0	38
157	RMEL3, a novel BRAFV600E-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma. <i>Oncotarget</i> , 2016, 7, 36711-36718.	1.8	25
158	Cross-Presentation Is a Source of Tumor Antigens for Multiple Myeloma Immunotherapy. <i>Blood</i> , 2016, 128, 2104-2104.	1.4	0
159	Genomic Classification of Cutaneous Melanoma. <i>Cell</i> , 2015, 161, 1681-1696.	28.9	2,562
160	ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. <i>Cancer Research</i> , 2015, 75, 3554-3567.	0.9	18
161	The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. <i>Cancer Cell</i> , 2015, 28, 515-528.	16.8	426
162	Genetic analysis of the uveal melanoma C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 357-359.	3.3	25

#	ARTICLE	IF	CITATIONS
163	Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 508-515.	0.7	138
164	HotSpotter: efficient visualization of driver mutations. <i>BMC Genomics</i> , 2014, 15, 1044.	2.8	8
165	TCRs Genetically Linked to CD28 and CD3 ζ Do Not Mismatch with Endogenous TCR Chains and Mediate Enhanced T Cell Persistence and Anti-Melanoma Activity. <i>Journal of Immunology</i> , 2014, 193, 5315-5326.	0.8	36
166	Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 10660-10665.	7.1	171
167	Cathepsin G Is Broadly Expressed By AML and Is an Effective Immunotherapeutic Target Against AML in Vivo. <i>Blood</i> , 2014, 124, 3761-3761.	1.4	0
168	Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells. <i>Journal of Visualized Experiments</i> , 2013, , e50058.	0.3	17
169	Microcystin-LR, a protein phosphatase inhibitor, induces alterations in mitotic chromatin and microtubule organization leading to the formation of micronuclei in <i>Vicia faba</i> . <i>Annals of Botany</i> , 2012, 110, 797-808.	2.9	19
170	Performance analysis of finite-source retrial queues operating in random environments. <i>International Journal of Operational Research</i> , 2007, 2, 254.	0.2	13
171	Performance analysis of finite-source retrial queues with nonreliable heterogeneous servers. <i>Journal of Mathematical Sciences</i> , 2007, 146, 6033-6038.	0.4	17
172	Heterogeneous Finite-Source Retrial Queues with Server Subject to Breakdowns and Repairs. <i>Journal of Mathematical Sciences</i> , 2006, 132, 677-685.	0.4	22
173	Homogeneous finite-source retrial queues with server subject to breakdowns and repairs. <i>Mathematical and Computer Modelling</i> , 2005, 42, 673-682.	2.0	60